| Inozyme Pharma Inc (INZY) | |||
|---|---|---|---|
| 4.74 0.09 (1.94%) | 05-03 16:00 | ||
| Open: | 4.75 | Pre. Close: | 4.65 |
| High: | 4.84 | Low: | 4.685 |
| Volume: | 323,223 | Market Cap: | 293(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 7.49 One year: 9.10 |
| Support: | Support1: 4.18 Support2: 3.48 |
| Resistance: | Resistance1: 6.41 Resistance2: 7.80 |
| Pivot: | 4.54  |
| Moving Averages: | MA(5): 4.57  MA(20): 4.75 MA(100): 5.22 MA(250): 4.96 |
| MACD: | MACD(12,26): -0.36 Signal(12,26,9): -0.40 |
| %K %D: | %K(14,3): 46.22 %D(3): 33.43 |
| RSI: | RSI(14): 42.49 |
| 52-Week: | High: 7.795 Low: 2.689 Change(%): -19.5 |
| Average Vol(K): | 3-Month: 702 10-Days: 573 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 4.847 - 4.867 | 4.867 - 4.887 |
| Low: | 4.633 - 4.653 | 4.653 - 4.673 |
| Close: | 4.707 - 4.742 | 4.742 - 4.778 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ INZY ] has closed below upper band by 16.9%. Bollinger Bands are 60.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
| Company profile |
|---|
| Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Underperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Select | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 61.77 |
| Shares Float (M) | 34.13 |
| % Held by Insiders | 0.66 |
| % Held by Institutions | 92.99 |
| Shares Short (K) | 2580 |
| Shares Short Prior Month (K) | 2320 |
| Stock Financials | |
|---|---|
| EPS | -1.370 |
| Book Value (p.s.) | 2.270 |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | -27.8 |
| Return on Equity (ttm) | -55.0 |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | -1.211 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -70.67 |
| Levered Free Cash Flow (M) | -46.05 |
| Stock Valuation | |
|---|---|
| PE Ratio | -3.46 |
| PEG Ratio | -0.23 |
| Price to Book value | 2.09 |
| Price to Sales | |
| Price to Cash Flow | -4.14 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
